By Sabela Ojea
Hims & Hers is expanding its weight-loss offering on its telehealth platform with the addition of Eli Lilly's Zepbound prescription and generic liraglutide.
The stock was up 7% to $31.62 in afternoon trading. Shares have risen around 31% year to date.
The telehealth-consultation platform on Tuesday said its aim is to bring customers more treatment options that best suit their needs.
"We've now expanded that choice even further by adding access to generic liraglutide and branded tirzepatide through our platform," the company said.
Hims & Hers' platform already offers weight-loss brands including Novo Nordisk's Ozempic and Wegovy.
Hims & Hers plans to continue expanding its weight loss offering to deliver a more personalized experience to its customer base, the company added.
"All of this is part of our long-term commitment to build the most comprehensive and personalized digital health platform for weight loss and beyond," Hims & Hers said.
Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix
(END) Dow Jones Newswires
April 01, 2025 15:02 ET (19:02 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。